首页 工具
登录
购物车
Bevacizumab

Bevacizumab

产品编号 T9904   CAS 216974-75-3

Bevacizumab 是一种人源化单克隆抗体,能以高亲和力与所有血管内皮生长因子-A 异构体特异性结合。

TargetMol的所有产品和服务仅用于科学研究,不能被用于人体,我们也不向个人提供产品和服务。
Bevacizumab Chemical Structure
Bevacizumab, CAS 216974-75-3
规格 价格/CNY 货期 数量
1 mg ¥ 1,320 现货
2 mg ¥ 1,990 现货
5 mg ¥ 3,370 5日内发货
千万补贴 助力科研
BCA蛋白浓度测定试剂盒限时半价
Venetoclax限时半价
产品目录号及名称: Bevacizumab (T9904)
点击图片重新获取验证码
选择批次  
抗体浓度: 27.1 mg/mL
纯度: 98.50%
抗体浓度: 27.1 mg/mL
纯度: 98.50%
抗体浓度: 2.36 mg/mL
更多批次查询请联系客服
生物活性
化学信息
存储 & 溶解度
参考文献
产品描述 Bevacizumab, a humanized monoclonal antibody, specifically and with high affinity binds to all isoforms of VEGF-A.
激酶实验 The binding kinetics of Bevacizumab or FD006 to VEGF is measured using Bio-Layer Inter-Ferometry on Octet RED. The assay is conducted at 30°C in PBS buffer. Sensor tips are pre-wet for 15 mins in buffer immediately prior to use, and the microplates are filled with 200 μL per well of diluted samples (VEGF) or buffer and agitated at 1000 rpm. The anti-human IgG biosensor are pre-saturated with Bevacizumab or FD006 (10 μg/mL) and washed in buffer for 120 seconds, and then transferred to VEGF at concentrations of 10 μg/mL, 3 μg/mL and 1 μg/mL. The VEGF association and dissociation rates are measured for 5mins and 10mins, respectively. The Kinetics parameters (Kon and Koff) and affinities (KD) are calculated from a non-linear global fit using the Octet analysis software. Multiple independent measurements are performed[2].
细胞实验 Human umbilical vein endothelial cells (HUVECs) (1×104 cells/100 μL/well) are seeded in 96-well plates and cultured at 37 for 14 h with Endothelial Cell Medium supplemented with 5% heat-inactivated FCS, 100 U/mL Penicillin, 100 U/mL Streptomycin, and endothelial cell growth supplement. After low-serum starvation overnight, cells are treated with different concentrations of FD006 or Bevacizumab which are pre-incubated with 10 ng/mL VEGF for 30 minutes and incubated at 37, 5% CO2 for 72 hours. Then, 10 μL CCK8 is added to each well and incubated for another 4 hours. The absorbance is measured by spectrophotometer at 450 nm to determine the cell viability[2].
化合物与蛋白结合的复合物

T9904_1

Crystal structure of Fab fragment of bevacizumab bound to DNA aptamer

分子量 149 kDa
CAS No. 216974-75-3

存储

store at low temperature | store at -20°C

TargetMol Calculator计算器

摩尔浓度计算器
稀释计算器
配液计算器
分子量计算器
=
X
X
X
=
X
=
/
g/mol

输入分子式,点击计算,可计算出产品的分子量。

TargetMol Library Books参考文献

1. Tan H, et al. 99mTc-labeled bevacizumab for detecting atherosclerotic plaque linked to plaque neovascularization and monitoring antiangiogenic effects of atorvastatin treatment in ApoE-/-mice. Sci Rep. 2017 Jun 14;7(1):3504. 2. Wang Q, et al. Pharmacological characteristics and efficacy of a novel anti-angiogenic antibody FD006 in corneal neovascularization. BMC Biotechnol. 2014 Feb 27;14:17. 3. Di Mauro C, et al. Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. Br J Cancer. 2017 May 23;116(11):1425-1435. 4. Yang X, Zheng Y, Tan J, et al. MiR-199a-5p-HIF-1α-STAT3 positive feed-back loop contributes to the progression of NSCLC[J]. 2020

TargetMol Library Books文献引用

1. Yang X, Zheng Y, Tan J, et al. MiR-199a-5p–HIF-1α-STAT3 Positive Feedback Loop Contributes to the Progression of Non-Small Cell Lung Cancer. Frontiers in Cell and Developmental Biology. 2021: 1931.
Icrucumab FGFR1/VEGFR2-IN-1 Carvedilol phosphate hemihydrate Tesevatinib VEGFR-2-IN-33 Decursinol angelate SU11274 Treprostinil Sodium

TargetMol Calculator剂量换算

对于不同动物的给药剂量换算,您也可以参考 更多...

TargetMol Calculator 体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。

第一步:请输入动物实验的基本信息
剂量
mg/kg
每只动物体重
g
给药体积
μL
动物数量
第二步:请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
% Tween 80
% ddH2O
计算 重置

技术支持

您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。

Keywords

Bevacizumab 216974-75-3 Angiogenesis Tyrosine Kinase/Adaptors VEGFR Inhibitor inhibitor inhibit

 

TargetMol Loading
陶术
生物
TargetMol®中国区唯一合作伙伴
点击进入陶术生物官网陶术生物
联系我们
400-820-0310

上海市静安区江场三路238号8楼